Nicox SA (OTCMKTS:NICXF – Get Free Report) saw a significant decrease in short interest in the month of February. As of February 27th, there was short interest totaling 21 shares, a decrease of 99.9% from the February 12th total of 20,021 shares. Approximately 0.0% of the shares of the company are sold short. Based on an average daily volume of 0 shares, the short-interest ratio is presently ∞ days. Based on an average daily volume of 0 shares, the short-interest ratio is presently ∞ days. Approximately 0.0% of the shares of the company are sold short.
Nicox Price Performance
OTCMKTS:NICXF opened at $0.30 on Thursday. Nicox has a 12 month low of $0.25 and a 12 month high of $0.30. The company has a 50 day simple moving average of $0.30 and a two-hundred day simple moving average of $0.30.
Nicox Company Profile
Nicox is a global biopharmaceutical company focused on the research, development and commercialization of innovative treatments for eye diseases. The company’s therapeutic approach centers on nitric oxide–donating compounds and anti-inflammatory agents designed to address glaucoma, ocular surface disorders and allergic eye conditions. With a pipeline spanning pre-clinical to late-stage clinical programs, Nicox aims to bring new modalities to market that target unmet needs in ophthalmology.
The company’s lead commercial product, ZERVIATE® (ciclesonide ophthalmic solution), is indicated for the relief of ocular itching associated with allergic conjunctivitis.
See Also
- Five stocks we like better than Nicox
- Is Trump Done? Shocking leak…
- The gold chart Wall Street is terrified of…
- I tried out Elon Musk’s new AI tech — it floored me
- “I just bought 10,000 shares of a $5 stock…”
- Elon Musk’s $1 Quadrillion AI IPO
Receive News & Ratings for Nicox Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nicox and related companies with MarketBeat.com's FREE daily email newsletter.
